{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:40:29Z","timestamp":1789371629352,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12985-017-0811-8","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T13:15:09Z","timestamp":1502716509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["An equine herpesvirus type 1 (EHV-1) vector expressing Rift Valley fever virus (RVFV) Gn and Gc induces neutralizing antibodies in sheep"],"prefix":"10.1186","volume":"14","author":[{"given":"Abdelrahman","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Elmanzalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanggang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando Mario","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Osterrieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"issue":"8","key":"811_CR1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/156652405774962263","volume":"5","author":"R Flick","year":"2005","unstructured":"Flick R, Bouloy M. Rift Valley fever virus. Curr Mol Med. 2005;5(8):827\u201334.","journal-title":"Curr Mol Med"},{"issue":"2","key":"811_CR2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.20506\/rst.23.2.1500","volume":"23","author":"GH Gerdes","year":"2004","unstructured":"Gerdes GH. Rift Valley fever. Rev Sci Tech. 2004;23(2):613\u201323.","journal-title":"Rev Sci Tech"},{"issue":"Suppl 4","key":"811_CR3","doi-asserted-by":"crossref","first-page":"S743","DOI":"10.1093\/clinids\/11.Supplement_4.S743","volume":"11","author":"CJ Peters","year":"1989","unstructured":"Peters CJ, Liu CT, Anderson GW Jr, Morrill JC, Jahrling PB. Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted. Rev Infect Dis. 1989;11(Suppl 4):S743\u20139.","journal-title":"Rev Infect Dis"},{"issue":"2","key":"811_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0924-8579(02)00295-9","volume":"21","author":"HH Balkhy","year":"2003","unstructured":"Balkhy HH, Memish ZA. Rift Valley fever: an uninvited zoonosis in the Arabian peninsula. Int J Antimicrob Agents. 2003;21(2):153\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"811_CR5","first-page":"65","volume":"10","author":"BC Easterday","year":"1965","unstructured":"Easterday BC. Rift valley fever. Adv Vet Sci. 1965;10:65\u2013127.","journal-title":"Adv Vet Sci"},{"issue":"8","key":"811_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1086\/378747","volume":"37","author":"TA Madani","year":"2003","unstructured":"Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin infect Dis. 2003;37(8):1084\u201392. doi: 10.1086\/378747 .","journal-title":"Clin infect Dis"},{"issue":"6","key":"811_CR7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0035-9203(79)90006-3","volume":"73","author":"LW Laughlin","year":"1979","unstructured":"Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg. 1979;73(6):630\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2 Suppl","key":"811_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","volume":"83","author":"M Mohamed","year":"2010","unstructured":"Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, et al. Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007. Am J Trop Med Hyg. 2010;83(2 Suppl):22\u20137. doi: 10.4269\/ajtmh.2010.09-0318 .","journal-title":"Am J Trop Med Hyg"},{"issue":"Pt 6","key":"811_CR9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1099\/0022-1317-75-6-1345","volume":"75","author":"R Muller","year":"1994","unstructured":"Muller R, Poch O, Delarue M, Bishop DH, Bouloy M. Rift Valley fever virus L segment: correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases. J Gen Virol. 1994;75(Pt 6):1345\u201352.","journal-title":"J Gen Virol"},{"issue":"2","key":"811_CR10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0042-6822(91)90087-R","volume":"180","author":"C Giorgi","year":"1991","unstructured":"Giorgi C, Accardi L, Nicoletti L, Gro MC, Takehara K, Hilditch C, et al. Sequences and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses. Virology. 1991;180(2):738\u201353.","journal-title":"Virology"},{"issue":"1","key":"811_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0042-6822(86)90114-5","volume":"151","author":"MS Collett","year":"1986","unstructured":"Collett MS. Messenger RNA of the M segment RNA of Rift Valley fever virus. Virology. 1986;151(1):151\u20136.","journal-title":"Virology"},{"issue":"27","key":"811_CR12","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","volume":"28","author":"J Kortekaas","year":"2010","unstructured":"Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 2010;28(27):4394\u2013401. doi: 10.1016\/j.vaccine.2010.04.048 .","journal-title":"Vaccine"},{"issue":"11","key":"811_CR13","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1128\/CVI.00182-09","volume":"16","author":"DH Holman","year":"2009","unstructured":"Holman DH, Penn-Nicholson A, Wang D, Woraratanadharm J, Harr MK, Luo M, et al. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity. Clin Vaccine Immunol. 2009;16(11):1624\u201332. doi: 10.1128\/CVI.00182-09 .","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"811_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","volume":"357","author":"SR Gerrard","year":"2007","unstructured":"Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology. 2007;357(2):124\u201333. doi: 10.1016\/j.virol.2006.08.002 .","journal-title":"Virology"},{"issue":"8","key":"811_CR15","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1128\/JVI.02483-08","volume":"83","author":"JT Huiskonen","year":"2009","unstructured":"Huiskonen JT, Overby AK, Weber F, Grunewald K. Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers. J Virol. 2009;83(8):3762\u20139. doi: 10.1128\/JVI.02483-08 .","journal-title":"J Virol"},{"issue":"7","key":"811_CR16","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","volume":"7","author":"E Lopez-Gil","year":"2013","unstructured":"Lopez-Gil E, Lorenzo G, Hevia E, Borrego B, Eiden M, Groschup M, et al. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+\u2212T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl Trop Dis. 2013;7(7):e2309. doi: 10.1371\/journal.pntd.0002309 .","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"811_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","volume":"14","author":"B Faburay","year":"2014","unstructured":"Faburay B, Lebedev M, McVey DS, Wilson W, Morozov I, Young A, et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis. 2014;14(10):746\u201356. doi: 10.1089\/vbz.2014.1650 .","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"12","key":"811_CR18","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1128\/CVI.00220-10","volume":"17","author":"RK Soi","year":"2010","unstructured":"Soi RK, Rurangirwa FR, McGuire TC, Rwambo PM, DeMartini JC, Crawford TB. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol. 2010;17(12):1842\u20139. doi: 10.1128\/CVI.00220-10 .","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"811_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","volume":"397","author":"RB Mandell","year":"2010","unstructured":"Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, Holbrook MR, et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology. 2010;397(1):187\u201398. doi: 10.1016\/j.virol.2009.11.001 .","journal-title":"Virology"},{"issue":"11","key":"811_CR20","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","volume":"28","author":"SM Boer de","year":"2010","unstructured":"de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, Rottier PJ, et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine. 2010;28(11):2330\u20139. doi: 10.1016\/j.vaccine.2009.12.062 .","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"811_CR21","doi-asserted-by":"publisher","first-page":"D69","DOI":"10.1016\/j.vaccine.2009.07.046","volume":"27","author":"T Ikegami","year":"2009","unstructured":"Ikegami T, Makino S. Rift valley fever vaccines. Vaccine. 2009;27(Suppl 4):D69\u201372. doi: 10.1016\/j.vaccine.2009.07.046 .","journal-title":"Vaccine"},{"issue":"36","key":"811_CR22","doi-asserted-by":"publisher","first-page":"14926","DOI":"10.1073\/pnas.1112149108","volume":"108","author":"JF Papin","year":"2011","unstructured":"Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, Holbrook MR, et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A. 2011;108(36):14926\u201331. doi: 10.1073\/pnas.1112149108 .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"811_CR23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","author":"CS Schmaljohn","year":"1989","unstructured":"Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology. 1989;170(1):184\u201392.","journal-title":"Virology"},{"issue":"6","key":"811_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","author":"B Botros","year":"2006","unstructured":"Botros B, Omar A, Elian K, Mohamed G, Soliman A, Salib A, et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006;78(6):787\u201391. doi: 10.1002\/jmv.20624 .","journal-title":"J Med Virol"},{"issue":"2","key":"811_CR25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","volume":"3","author":"JD Kark","year":"1985","unstructured":"Kark JD, Aynor Y, Peters CJ. A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection. Vaccine. 1985;3(2):117\u201322.","journal-title":"Vaccine"},{"issue":"5","key":"811_CR26","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","volume":"116","author":"JD Kark","year":"1982","unstructured":"Kark JD, Aynor Y, Peters CJ. A rift valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol. 1982;116(5):808\u201320.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"811_CR27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","volume":"4","author":"GF Meadors","year":"1986","unstructured":"Meadors GF, Gibbs PH, Peters CJ. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine. 1986;4(3):179\u201384.","journal-title":"Vaccine"},{"issue":"1","key":"811_CR28","first-page":"1","volume":"43","author":"PH Hubert","year":"1996","unstructured":"Hubert PH, Birkenmaier S, Rziha HJ, Osterrieder N. Alterations in the equine herpesvirus type-1 (EHV-1) strain RacH during attenuation. Zentralblatt fur Veterinarmedizin Reihe B Journal of veterinary medicine Series B. 1996;43(1):1\u201314.","journal-title":"Zentralblatt fur Veterinarmedizin Reihe B Journal of veterinary medicine Series B"},{"issue":"9","key":"811_CR29","first-page":"351","volume":"112","author":"A Neubauer","year":"1999","unstructured":"Neubauer A, Meindl A, Osterrieder N. Mutations in the US2 and glycoprotein B genes of the equine herpesvirus 1 vaccine strain RacH have no effects on its attenuation. Berliner und Munchener tierarztliche Wochenschrift. 1999;112(9):351\u20134.","journal-title":"Berliner und Munchener tierarztliche Wochenschrift"},{"issue":"2","key":"811_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1006\/viro.1996.0652","volume":"226","author":"N Osterrieder","year":"1996","unstructured":"Osterrieder N, Neubauer A, Brandmuller C, Kaaden OR, O'Callaghan DJ. The equine herpesvirus 1 IR6 protein influences virus growth at elevated temperature and is a major determinant of virulence. Virology. 1996;226(2):243\u201351. doi: 10.1006\/viro.1996.0652 .","journal-title":"Virology"},{"issue":"2","key":"811_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1006\/viro.2001.1277","volume":"293","author":"J Rudolph","year":"2002","unstructured":"Rudolph J, Osterrieder N. Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Virology. 2002;293(2):356\u201367. doi: 10.1006\/viro.2001.1277 .","journal-title":"Virology"},{"issue":"19","key":"811_CR32","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.vaccine.2008.02.064","volume":"26","author":"C Rosas","year":"2008","unstructured":"Rosas C, Van de Walle GR, Metzger SM, Hoelzer K, Dubovi EJ, Kim SG, et al. Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza. Vaccine. 2008;26(19):2335\u201343. doi: 10.1016\/j.vaccine.2008.02.064 .","journal-title":"Vaccine"},{"key":"811_CR33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.virusres.2006.12.009","volume":"125","author":"CT Rosas","year":"2007","unstructured":"Rosas CT, Tischer BK, Perkins GA, Wagner B, Goodman LB, Osterrieder N. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). Virus Res. 2007;125:69\u201378.","journal-title":"Virus Res"},{"key":"811_CR34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/vir.0.82528-0","volume":"88","author":"CT Rosas","year":"2007","unstructured":"Rosas CT, K\u00f6nig P, Beer M, Dubovi EJ, Tischer BK, Osterrieder N. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins. J Gen Virol. 2007;88:748\u201357.","journal-title":"J Gen Virol"},{"issue":"1","key":"811_CR35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4269\/ajtmh.2008.78.83","volume":"78","author":"CT Rosas","year":"2008","unstructured":"Rosas CT, Paessler S, Ni H, Osterrieder N. Protection of mice by equine herpesvirus type 1 based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies. Am J Trop Med Hyg. 2008;78(1):83\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"811_CR36","doi-asserted-by":"publisher","unstructured":"Said A, Damiani A, Ma G, Kalthoff D, Beer M, Osterrieder N. An equine herpesvirus 1 (EHV-1) vectored H1 vaccine protects against challenge with swine-origin influenza virus H1N1. Vet Microbiol 2011;154(1\u20132):113-123. doi: 10.1016\/j.vetmic.2011.07.003 . S0378\u20131135(11)00385\u20133.","DOI":"10.1016\/j.vetmic.2011.07.003"},{"issue":"4","key":"811_CR37","doi-asserted-by":"publisher","first-page":"e34425","DOI":"10.1371\/journal.pone.0034425","volume":"7","author":"G Ma","year":"2012","unstructured":"Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One. 2012;7(4):e34425. doi: 10.1371\/journal.pone.0034425 .","journal-title":"PLoS One"},{"issue":"2","key":"811_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.virusres.2013.01.004","volume":"173","author":"A Said","year":"2013","unstructured":"Said A, Lange E, Beer M, Damiani A, Osterrieder N. Recombinant equine herpesvirus 1 (EHV-1) vaccine protects pigs against challenge with influenza a(H1N1)pmd09. Virus Res. 2013;173(2):371\u20136. doi: 10.1016\/j.virusres.2013.01.004 .","journal-title":"Virus Res"},{"issue":"2","key":"811_CR39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2144\/000112096","volume":"40","author":"BK Tischer","year":"2006","unstructured":"Tischer BK, von Einem J, Kaufer B, Osterrieder N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia Coli. BioTechniques. 2006;40(2):191\u20137.","journal-title":"BioTechniques"},{"issue":"6","key":"811_CR40","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1128\/JVI.78.6.3003-3013.2004","volume":"78","author":"J Einem von","year":"2004","unstructured":"von Einem J, Wellington J, Whalley JM, Osterrieder K, O'Callaghan DJ, Osterrieder N. The truncated form of glycoprotein gp2 of equine herpesvirus 1 (EHV-1) vaccine strain KyA is not functionally equivalent to full-length gp2 encoded by EHV-1 wild-type strain RacL11. J Virol. 2004;78(6):3003\u201313.","journal-title":"J Virol"},{"issue":"1","key":"811_CR41","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.4102\/jsava.v85i1.1075","volume":"85","author":"S Fagbo","year":"2014","unstructured":"Fagbo S, Coetzer JA, Venter EH. Seroprevalence of Rift Valley fever and lumpy skin disease in African buffalo (Syncerus Caffer) in the Kruger National Park and Hluhluwe-iMfolozi park, South Africa. J S Afr Vet Assoc. 2014;85(1):1075. doi: 10.4102\/jsava.v85i1.1075 .","journal-title":"J S Afr Vet Assoc"},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"27719","DOI":"10.1038\/srep27719","volume":"6","author":"B Faburay","year":"2016","unstructured":"Faburay B, Wilson WC, Gaudreault NN, Davis AS, Shivanna V, Bawa B, et al. A recombinant Rift Valley fever virus glycoprotein subunit vaccine confers full protection against Rift Valley fever challenge in sheep. Sci Rep. 2016;6:27719. doi: 10.1038\/srep27719 .","journal-title":"Sci Rep"},{"issue":"2","key":"811_CR43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0042-6822(89)90442-X","volume":"170","author":"LT Kakach","year":"1989","unstructured":"Kakach LT, Suzich JA, Collett MS. Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation. Virology. 1989;170(2):505\u201310.","journal-title":"Virology"},{"issue":"1","key":"811_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","volume":"366","author":"R Gorchakov","year":"2007","unstructured":"Gorchakov R, Volkova E, Yun N, Petrakova O, Linde NS, Paessler S, et al. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology. 2007;366(1):212\u201325. doi: 10.1016\/j.virol.2007.04.014 .","journal-title":"Virology"},{"issue":"Pt 7","key":"811_CR45","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1099\/vir.0.042754-0","volume":"93","author":"E Ayari-Fakhfakh","year":"2012","unstructured":"Ayari-Fakhfakh E, do Valle TZ, Guillemot L, Panthier JJ, Bouloy M, Ghram A, et al. MBT\/pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines. J Gen Virol. 2012;93(Pt 7):1456\u201364. doi: 10.1099\/vir.0.042754-0 .","journal-title":"J Gen Virol"},{"issue":"9","key":"811_CR46","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1128\/JVI.79.9.5445-5454.2005","volume":"79","author":"S Trapp","year":"2005","unstructured":"Trapp S, von Einem J, Hofmann H, Kostler J, Wild J, Wagner R, et al. Potential of equine herpesvirus 1 as a vector for immunization. J Virol. 2005;79(9):5445\u201354. doi: 10.1128\/JVI.79.9.5445-5454.2005 .","journal-title":"J Virol"},{"issue":"7","key":"811_CR47","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1128\/JVI.06994-11","volume":"86","author":"G Ma","year":"2012","unstructured":"Ma G, Feineis S, Osterrieder N, Van de Walle GR. Identification and characterization of equine herpesvirus type 1 pUL56 and its role in virus-induced downregulation of major histocompatibility complex class I. J Virol. 2012;86(7):3554\u201363. doi: 10.1128\/JVI.06994-11 .","journal-title":"J Virol"},{"issue":"15","key":"811_CR48","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1128\/JVI.00891-12","volume":"86","author":"A Said","year":"2012","unstructured":"Said A, Azab W, Damiani A, Osterrieder N. Equine Herpesvirus type 4 UL56 and UL49.5 proteins Downregulate cell surface major Histocompatibility complex class I expression independently of each other. J Virol. 2012;86(15):8059\u201371. doi: 10.1128\/JVI.00891-12 .","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-017-0811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T11:26:31Z","timestamp":1570015591000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-017-0811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s12985-017-0811-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]},"article-number":"154"}}